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RESEARCH ARTICLE 
Abstract 
The aim of this study was to investigate if dietary administration of γ-am inobutyric acid (GABA)-producing 
Lactobacillus brevis DPC 6108 and pure GABA exert protective effects against the development of 
diabetes in streptozotocin (STZ)-induced diabetic Sprague Dawley rats. In a first experiment, healthy rats 
were divided in 3 groups (n=10/group) receiving placebo, 2.6 mg/kg body weight (bw) pure GABA or L. 
brevis DPC 6108 (-'109 microorganisms). In a second experiment, rats (n=15/group) were randomised to 
five groups and four of these received an injection of STZ to induce type 1 diabetes. Diabetic and non- 
diabetic controls received placebo [4% (w/v) yeast extract in dH2O], while the other three diabetic groups 
received one of the following dietary supplements: 
2.6 mg/kg bw GABA (low GABA), 200 mg/kg bw GABA (high GABA) or -'109 L. brevis DPC 6108. L. 
brevis DPC 6108 supplementation was associated with increased serum insulin levels (P<0.05), but did 
not alter other metabolic markers in healthy rats. Diabetes induced by STZ injection decreased body 
weight (P<0.05), increased intestinal length (P<0.05) and stimulated water and food intake. Insulin was 
decreased (P<0.05), whereas glucose was increased (P<0.001) in all diabetic groups, compared with non- 
diabetic controls. A decrease (P<0.01) in glucose levels was observed in diabetic rats receiving L. brevis 
DPC 6108, compared with diabetic-controls. Both the composition and 
diversity of the intestinal microbiota were affected by diabetes. Microbial diversity in diabetic rats 
supplemented with low GABA was not reduced (P>0.05), compared with non-diabetic controls while all 
other diabetic groups displayed reduced diversity (P<0.05). L. brevis DPC 6108 attenuated 
hyperglycaemia induced by diabetes but additional studies are needed to understand the mechanisms 
involved in this reduction. 
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1. Introduction 
Type 1 diabetes (T1 D) is a chronic and progressive disorder in which genetically susceptible individuals 
may develop an autoimmune response leading to pancreatic β-cell damage and insulin insufficiency 
(Atkinson and Eisenbarth, 2001). Recent research has described an altered intestinal microbialecosystem 
associated with both type 1 (Brown et al., 2011 ;De Goffau et al., 2013; Giongo et al., 2011; Murri et al., 
2013; Patterson et al., 2015) and type 2 diabetes (Cani, 2012; Karlsson et al., 2012; Qin et al., 2012; 
Zhang et al., 2013). Insulin administration is the main therapeutic strategy for T1 D and although there 
have been improvements in treatment achieving euglycaemia without risk of severe hypoglycaemia 
requires strict control of glucose levels (Atkinson and Eisenbarth, 2001). γ-aminobutyric acid (GABA) may 
constitute a very effective therapy for T1 D. Soltani et al. (2011) have previously demonstrated that 
injections of GABA not only promoted β-cells proliferation, but also inhibited immune responses, reversing 
the disease in severely diabetic mice. GABA had also previously demonstrated its effectiveness towards 
preventing type 2 diabetes progression by improving glucose tolerance and insulin sensitivity in high fat 
diet induced obese mice (Tianet al., 2011 b). Furthermore, GABA-producing bacteriahave been isolated 
from several food sources and fromthe human gut (Barrett et al., 2012; Park and Oh, 2007;Seo et al., 
201 3).GABA is the major inhibitory neurotransmitter in thecentral nervous system (CNS). In peripheral 
tissues, GABAacts not only as a neurotransmitter in the enteric andparasympathetic nervous systems but 
also as a hormonein non-neuronal tissues (Erdö, 1992). In the endocrinepancreas, GABA is produced by 
β-cells and once released,activates ionotropic GABAA and metabotropic GABABreceptors in both α- and 
β-cells (Bonaventura et al., 2008;Dong et al., 2006). Through a paracrine signal, GABAreleased from β-
cells inhibits glucagon release from α-cells(Bailey et al., 2007), whereas an autocrine signal increasesor 
decreases insulin secretion from β-cells, depending onextracellular glucose levels (Dong et al., 2006). 
GABA isproduced through the conversion of L-glutamate by theenzyme glutamate decarboxylase and 
different types ofbacteria produce GABA as a response to adverse acidicenvironmental conditions (Cotter 
et al., 2001; Jung andKim, 2003; Sanders et al., 1998). Indeed, potential probioticbacteria isolated from 
the human gastrointestinal tract havebeen shown to efficiently convert glutamate to GABA invitro (Barrett 
et al., 2012).A disturbed microbiota is a potential environmentalfactor contributing toward metabolic 
disease, affectingthe immune system and even influencing the perceptionof pain and behaviour (Brown et 
al., 2011; Cryan andDinan, 2012; Lam et al., 2011). Interestingly, the use ofdietary strategies, such as 
probiotics and prebiotics may beeffective for the alleviation of these disorders through theproduction of 
bioactive compounds that may act directlyor indirectly on host metabolism (Lyte, 2011). Thus,considering 
the role of GABA on glucose homeostasisand the evidence showing how probiotics may affect hosthealth, 
we investigated the impact of oral administration ofpure GABA and GABA-producing bacteria 
Lactobacillusbrevis DPC 6108 on the protection against the developmentof T1 D in streptozotocin (STZ)- 
induced diabetic rats. 
2. Materials and methods 
Animals 
All experimental procedures were performed in accordancewith the protocols approved by the University 
CollegeCork Ethics Committee, under a license issued fromthe Department of Health and Children. Male 
SpragueDawley rats, 5 weeks of age, were obtained from Harlan UK(Loughborough, UK) and housed 
under barrier-maintainedconditions. All animals were allowed to acclimatise forone week prior to 
commencement of the experiments.Animals were group-housed, with 5 animals per cage atstandard 
conditions (room temperature of 21 °C, with a 1 2-hlight-dark cycle, lights on at 07:00). All groups were fed 
adlibitum with Teklad Global rodent standard diet (#2018S;Harlan Laboratories, Loughborough, UK) and 
allowedfree access to food and water. Water containing either L.brevis DPC 6108, GABA (Sigma Aldrich, 
Arklow, Ireland)and/or placebo freeze-dried powder was the only watersupply provided to the animals 
throughout the experimentsand bottles were replaced daily. Two experiments wereconducted in this 
study – Experiment 1 using healthy ratsand Experiment 2 using STZ-induced diabetic rats. 
Lactobacillus brevis DPC 6108 and placebo preparation 
L. brevis DPC 6108 is an efficient GABA producer, withmaximum conversion in vitro when growing on 
DeMan Rogosa and Sharpe (MRS; Difco Laboratories, BD,Franklin Lakes, NJ, USA) broth supplemented 
with 30 mg/ml monosodium glutamate (MSG) (Barrett et al., 201 2).Rifampicin-resistant variants of L. 
brevis DPC 6108 wereisolated by spread-plating ~109 cfu from an overnightculture (1% inoculum) onto 
MRS agar (Difco Laboratories)containing 500 μg rifampicin/ml (Sigma Aldrich Ireland)and stocked at -80 
°C. Before freeze-drying, frozen stockswere plated in MRS agar and a single colony was isolated 
forinoculation in 10 ml fresh MRS broth supplemented with 30mg/ml MSG. The culture was incubated 
overnight at 37 °Cunder anaerobic conditions and then inoculated into 1 lMRS broth containing MSG and 
allowed to grow overnightat 37 °C under anaerobic conditions. The overnight culturealiquots were then 
inoculated into large volumes of MRScontaining MSG and allowed to grow overnight at 37 °Cunder 
anaerobic conditions. The overnight culture waswashed twice in phosphate buffered saline (Sigma 
AldrichIreland) and the pellet resuspended in 15% (w/v) trehalose(Sigma Aldrich Ireland) in dH2O 
(Experiment 1) or 4% (w/v)yeast extract (Difco Laboratories) in dH2O (Experiment 2).1 ml aliquots of 
bacterial culture were freeze-dried by usinga 24-h program (freeze temperature, -40 °C; condenserset 
point, -60 °C; vacuum set point, 600 mTorr). Vialscontaining 1 ml of placebo solution (15% (w/v) 
trehaloseor 4% (w/v) yeast extract) were freeze-dried using thesame programme. All the vials containing 
freeze-driedpowder were stored at -20 °C until use. Each animal thatreceived the bacterial strain 
consumed ~1×1 09 cfu/day.This was achieved by resuspending the freeze-dried powderin water, which 
rats consumed ad libitum. Freeze-driedaliquots were prepared every 2 weeks and were stored at-20 °C. 
The groups that did not receive the bacterial strainreceived placebo freeze-dried powder [15% (w/v) 
trehaloseor 4% (w/v) yeast extract in dH2O]. Freeze-dried powderunderwent continuous quality control of 
cell counts for theduration of the experiments by plating serial dilutions on MRS agar supplemented with 
100 μg/ml rifampicin andincubating plates anaerobically for 48 h at 37 °C. 
Faecal sample microbial analysis and GABA production assay 
Fresh faecal samples were taken every week for microbialanalysis in order to verify if the strain survived 
gut transit,rats were receiving enough bacterial cells and there wasno cross-contamination to the groups 
not receiving thestrain. Microbial analysis involved enumeration of the L.brevis DPC 6108 strain after 
plating serial dilutions onMRS agar supplemented with 100 μg rifampicin/ml (SigmaAldrich Ireland) and 
incubating anaerobically for 48 h at37 °C. In addition, isolated colonies were tested for GABAproduction 
as described previously (Barrett et al., 201 2).Briefly, isolated colonies were grown anaerobically in 
MRScontaining 3% (w/v) MSG at 37 °C for 55 h. Samples werethen deproteinised by mixing equal 
volumes of 24% (w/v)trichloroacetic acid and culture, allowed to stand for 1 0min and centrifuged at 
1 4,000×g for 10 min. Supernatantswere removed and diluted with 0.2 mol/l sodium citratebuffer, pH 2.2 to 
yield 250 nmol of each amino acid residue. Samples were then diluted with the internal 
standard,norleucine, to give a final concentration of 125 nm/ml.Amino acids were quantified using a Jeol 
JLC-500/V aminoacid analyser (Jeol Ltd., Garden City, UK) fitted with a JeolNa+ high-performance cation 
exchange column. 
Effects of GABA powder and Lactobacillus brevis DPC 6108 
Experiment 1 – effects on healthy rats 
Animals were divided into 3 groups with 10 rats per group,receiving either GABA (2.6 mg/kg bw + 15% w/v 
trehalose),L. brevis DPC 6108 (-'109 cells in 15% w/v trehalose) orplacebo (15% trehalose) mixed in the 
drinking water for5 weeks. All groups received 15% (w/v) trehalose as thissolution was used as 
cryoprotectant while freeze-dryingthe L. brevis DPC 6108. The standard diet used contained3.4% (w/w) 
glutamic acid and was a sufficient substrate forthe conversion to GABA by L. brevis DPC 6108 (Barrettet 
al., 2012). Body weight was assessed weekly. After 5weeks dietary intervention, animals were sacrificed 
bydecapitation and blood samples were collected, allowedto clot at 4 °C, centrifuged for 20 min at 2,000×g 
and theserum collected into clean microtubes. Liver was removedand flash-frozen on dry ice. All samples 
were stored at-80 °C prior to analyses. 
Experiment 2 – effects on streptozotocin-induced diabetic rats 
Animals were divided into 5 groups with 15 rats per group:non-diabetic control group and diabetic control 
groupreceived only placebo freeze-dried powder [4% (w/v) yeastextract], diabetic low dose GABA group 
received 2.6 mg/kg bw GABA powder, diabetic high dose GABA groupreceived 200 mg/kg bw GABA 
powder, and diabetic L.brevis DPC 6108 group received -'109 bacterial cells in 4%(w/v) yeast extract. 
GABA, L. brevis DPC 6108 and placebofreeze-dried powders were diluted in fresh drinking waterevery 
day throughout the 9-week trial period. Every groupreceived 4% (w/v) yeast extract as this solution was 
usedas cryoprotectant while freeze-drying L. brevis DPC 6108.On experimental week 3, type 1 diabetes 
was induced inrats in four of the groups by intraperitoneal injection with asingle dose of 60 mg/kg STZ 
(≥75% α-anomer basis; SigmaAldrich) freshly prepared in 50 mM sodium citrate buffer(pH 4.5) and 
injected within 10 to 15 min after dissolving,according to a previously described procedure (Wu andHuan, 
2008). The non-diabetic control group receivedan injection of citrate buffer only. Seven days post 
STZinjection,glucose levels were measured in triplicate using aContour Next blood glucose meter (Bayer) 
in blood samplescollected from a tail vein. Rats with glucose levels higherthan 200 mg/dl were considered 
diabetic and STZ-inducedrats that had lower glucose level were excluded. From atotal of 60 rats treated 
with STZ, three died 1-2 days afterinjection, whereas ten rats did not develop diabetes andwere excluded. 
In the remaining 47 rats, body weight andglucose levels were assessed weekly, while food intake 
andwater consumption were measured daily. After 9 weeksof dietary intervention rats were killed by 
decapitationand blood samples were collected, allowed to clot at 4 °C,centrifuged for 20 min at 2,000×g 
and the serum collectedinto clean microtubes. Liver and caecal contents wereremoved and flash-frozen 
on dry ice and small intestinallength was measured from individual rats. All samples werestored at -80 °C 
prior to analyses. 
Serum analyses 
Commercial kits were used for measurement of GABA andmetabolic markers in serum. GABA was 
determined usingthe GABA research ELISA kit (Invitech Ltd., Huntingdon,UK). Glucose was determined 
using the QuantiChromglucose assay (BioAssay Systems, Hayward, CA, USA),triglycerides were 
measured by using EnzyChromTriglyceride Assay kit (BioAssay Systems) and cholesterolusing LabAssay 
Cholesterol kit (Wako, Japan). Insulin,glucagon, c-peptide, peptide YY (PYY), active glucagon-
likepeptide1 (GLP-1), gastric inhibitory polypeptide (GIP)and leptin were measured using Rat Metabolic 
HormoneMagnetic Bead Panel (Merck Millipore, Schwalbach amTaunus, Germany). 
Liver analyses 
Hepatic lipids were extracted according to the method of Folch et al. (1957). After extraction, samples were 
driedunder a stream of nitrogen and resuspended in 5% (v/v)solution of Triton X-1 00 in distilled water. 
Triglyceride concentration was determined using the commercial kitEnzyChrom Triglyceride Assay 
(BioAssay Systems) andcholesterol using LabAssay Cholesterol kit (Wako, Japan). 
Microbial DNA extraction, 1 6s rRNA amplification and Illumina MiSeq sequencing 
Caecal contents were collected from individual rats 6 weekspost-STZ injection. Total metagenomic DNA 
was extractedfrom caecal contents with the QIamp DNA Stool Mini Kit(Qiagen, Hilden, Germany) where 
an additional bead beatingstep was incorporated into the protocol. Extracted DNA wasquantified using the 
Nanodrop 1000 spectrophotometer(Thermo Scientific, Dublin, Ireland). The V3-V4 variableregion of the 
16s rRNA gene was amplified from eachextracted DNA sample according to the 16S 
metagenomicsequencing library protocol (Illumina, San Diego, CA, USA).Initially the template DNA was 
amplified using primersspecific to the V3-V4 region of the 16s rRNA gene whichalso allowed for the 
Illumina overhang adaptor, where, theforward primer 
(5’TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGG NGGCWGCAG) andreverse primer 
(5’GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC) wereused. 
Each PCR reaction contained 2.5 μl DNA template,5 μl forward primer (1 μM), 5 μl reverse primer (1 
μM)(Sigma Aldrich) and 12.5 μl Kapa HiFi Hotstart Readmix(2×) (Kapa Bioscystems Inc., Wilmington, MA, 
USA). Thetemplate DNA was amplified under the following PCRconditions for a total of 25 cycles: 95 °C 
for 3 min and 30 srespectively (initialisation and denaturation), 55 °C for 30s (annealing), 72 °C for 30 s 
(elongation) followed by a finalelongation period of 5 min. A negative control reaction,whereby the 
template DNA was replaced with PCR gradewater, was employed to confirm lack of contamination 
andPCR products were visualised using gel electrophoresis (1 ×tris-acetate-EDTA buffer, 1.5% agarose 
gel, 1 00v) post-PCRreaction. Successful amplicons were then cleaned using theAMpure XP purification 
system (Beckman and Coulter,Takeley, UK). A second PCR reaction was then completedusing the 
previously amplified and purified DNA as thetemplate. Two indexing primers (Illumina Nextera XTindexing 
primers, Illumina) were used per sample to allowall samples to be pooled, sequenced on one flow cell 
andsubsequently identified bioinformatically. Each reactioncontained 25 μl Kapa HiFi HotStart ReadyMix 
(2×), 5 μltemplate DNA, 5 μl index 1 primer (N7xx), 5 μl index 2primer (S5xx) and 10 μl PCR grade water. 
PCR conditionswere the same as previously described with the samplesundergoing just 8 cycles instead 
of 25. PCR products thenunderwent the same electrophoresis and cleaning protocolsas described above. 
Samples were then quantified using theQubit 2.0 fluorometer (Invitrogen, Carlsbad, CA, USA) 
inconjunction with the high sensitivity DNA quantificationassay kit (Life technologies, Carlsbad, CA, USA). 
Allsamples were then pooled to an equimolar concentrationand the pool underwent a final cleaning step. 
Quality of thepool was determined using the Agilent Bioanalyser prior tosequencing. The sample pool was 
then denatured with 0.2M NaOH, diluted to 4 pM and combined with 10% (v/v)denatured 4 pM PhiX. 
Samples were then sequenced inhouse on the MiSeq sequencing platform at the TeagascNext 
Generation Sequencing Platform Centre (TeagascFood Research Centre, Moorepark, Ireland) using a 
2×300cycle V3 Kit following protocols as described by Illumina. 
Bioinformatic analysis 
300 base pair paired-end reads were joined using FLASH (fast length adjustment of short reads to improve 
genomeassemblies) (Magoc and Salzberg, 2011). Reads were furtherprocessed with the inclusion of 
quality filtering based ona quality score of >20 followed by subsequent removal ofsequences below length 
threshold using QIIME (Caporasoet al., 2010b). USEARCH v7 (64-bit) was then used fordenoising and 
chimera detection ad well as clusteringinto operational taxonomic units (OTUs) at 97% 
identity(http://www.drive5.com/usearch). PyNAST (Caporasoet al., 2010a) was used to align OTUs and 
taxonomy wasassigned by using BLAST (Altschul et al., 1990) against theSILVA SSURef database 
release 111 (Quast et al., 201 3).QIIME was used to generate alpha (Shannon, Simpson,Chao1, observed 
species and phylogenetic diversity) andbeta diversities, (Bray Curtis, Weighted and UnWeightedUnifrac) 
distance matrices (http://qiime.org). Principalcoordinate analysis (PCoA) plots were generated basedon 
the beta diversity distance matrices and were visualisedusing EMPeror v0.9.3-dev (Vazquez-Baeza et al., 
2013). 
Statistical analysis 
To assess whether differences between treatment groupswere significant, statistical analysis was 
performed by usingone factor ANOVA followed by Tukey’s or Dunnett’s posthoc multiple comparison tests 
(GraphPad Prism Software(Version 6.0), San Diego, CA, USA). Non-parametricKruskall-Wallis analysis 
using Dunn’s multiple comparisonstest was carried out to determine statistically significanttaxonomic 
differences between groups (GraphPad Prism). 
3. Results 
Survival of Lactobacillus brevis DPC 6108 through the gastrointestinal tract 
Quantification of the numbers of administered rifampicinresistantL. brevis strain in the faeces of rats 
confirmed itssurvival during gastrointestinal transit. Stool recovery of L.brevis DPC 6108 was ~1.1×107 
cfu/g faeces after 1 week offeeding and remained at similar numbers until the end ofexperiments. 
Colonies isolated from the plates were testedfor GABA production in order to assess if gastric transit 
affected ability of L. brevis DPC 6108 to produce GABA. All colonies tested produced similar quantities of 
GABA invitro when compared to the wild type strain (average of 5.8mg/ml, similar to the wild type (5.5 
mg/ml)). There was nocross-contamination between groups as L. brevis DPC 61 08was not detected in the 
stool of rats not receiving the strain. 
Effects of Lactobacillus brevis DPC 6108 on metabolic markers of healthy rats 
After 5 weeks supplementation with L. brevis DPC 6108,no differences in body weight gain, final body 
weight, livercholesterol and serum glucose were observed (data notshown). However, serum insulin levels 
were increased(P<0.05) in rats receiving L. brevis DPC 6108, whencompared with rats in the GABA 
supplemented and controlgroups (Table 1). 
Effects of GABA and Lactobacillus brevis DPC 6108 supplementation in induced-diabetic rats 
Effects on body weight, small intestine length, water and food intake 
Post-STZ injection, rats that developed diabetes continuedto lose body weight until the end of the 
experiment. Finalbody weights were significantly reduced in all diabetic rats,compared with non-diabetic 
control rats (P<0.001). Dietarysupplementation with GABA and L. brevis DPC 6108 didnot improve weight 
gain in diabetic rats. The abdomensof diabetic rats were distended, filled with a swollenintestine and small 
intestinal length was significantly longer,compared with those of non-diabetic control rats 
(P<0.001).Moreover, mean daily food and water consumption weresignificantly higher in diabetic rats, 
compared with thenon-diabetic control group (P<0.001), with no significantdifferences between treatment 
groups observed (Table 2). Diabetic rats exhibited polyuria and excessive faecal output. 
Effects on GABA levels in serum 
Serum analysis revealed a significant increase in GABAlevels in the diabetic-high GABA group, compared 
with thediabetic-low GABA, diabetic L. brevis DPC 6108 and bothdiabetic and non-diabetic control groups 
(P<0.05; Table 3). 
Effects on serum glucose levels and other metabolic markers 
Serum glucose levels were significantly increased inall diabetic groups, compared with the non-
diabeticcontrol group (P<0.001). However, lower glucose levelswere observed in rats receiving L. brevis 
DPC 6108supplementation relative to rats in the diabetic controlgroup (P<0.01). Insulin and C-peptide 
levels were significantly decreased, whereas glucagon was increasedin all diabetic groups, compared with 
the non-diabeticcontrol group (P<0.05; Table 3). GLP-1 and GIP serum levels were not affected in any of 
the groups. PYY was4- to 5-fold significantly higher in diabetic rats, comparedwith the non-diabetic control 
group (P<0.05), with nodifferences between treatments. Leptin is a hormoneproduced by adipose cells. 
Therefore, probably due to thelower adipose tissue mass in diabetic rats, serum leptin levels were 
significantly decreased in all diabetic groups,compared with the non-diabetic control group (P<0.001 ;Table 
3). 
 
  
Effects on serum cholesterol 
Serum cholesterol was significantly higher in diabetic ratssupplemented with the high dose of GABA, 
comparedwith rats in the diabetic and non-diabetic control groups(P<0.05). No differences in liver 
cholesterol were observedbetween groups. Serum and liver triglyceride levels weresignificantly higher in 
all diabetic groups, compared withthe non-diabetic control group (P<0.05). No significantdifferences were 
observed in serum and liver triglyceridelevels between treatment groups (Table 3). 
Effects on microbial diversity and microbial composition 
The microbial composition in caecal contents ofindividual rats was elucidated through high -
throughputDNA sequencing (Illumina MiSeq) of 16S rRNA (V3-V4)amplicons 9 weeks post GABA and L. 
brevis DPC 6108supplementation and 6 weeks post STZ injection. At the97% similarity level, alpha 
diversity values were calculatedfor species richness (Chao1), biodiversity (Shannon Index),observed 
species and species number relative to abundancewithin the sample (Simpson diversity index) (Figure 
1 ).All alpha diversity metrics were significantly lower inthe diabetic control, diabetic -high GABA and 
diabeticL. brevis DPC 6108 groups, compared with the nondiabeticcontrol group (P<0.05) (Figure 1). No 
significantdifferences across any of the five alpha diversity metricswere found between the diabetic-low 
GABA and nondiabeticcontrol groups (Figure 1). Chao1, phylogeneticdiversity and observed species were 
also significantly higherin the diabetic-low GABA group, compared with all otherdiabetic groups (P<0.05) 
(Figure 1). Principal coordinateanalysis (built upon the unweighted unifrac algorithm)revealed distinct 
clustering in the non-diabetic controlgroup only (Figure 2). This demonstrates a similarity in themicrobial 
composition of these rats within the non-diabeticcontrol group, commonly associated with such a 
controlledenvironment. All diabetic groups, irrespective of treatmentfailed to cluster distinctly but did 
separate from the nondiabeticcontrol group (Figure 2). The failure of individualrats within a group to 
cluster, distinctly suggests that them icrobial compositions of rats within each of the diabeticgroups are 
significantly different from each other. None ofthe treatments appeared to restore clustering either withina 
particular group or with the non-diabetic control group.This demonstrates that STZ-induced T1 D is a 
strong factordriving the differences in microbial populations, comparedwith the non-diabetic control group. 
Four rats from the diabetic-low GABA group appeared closest to the nondiabeticcontrol cluster, possibly 
indicating a more similarmicrobial taxonomy (Figure 2).Phylogenetic analysis (examined at phylum, family 
andgenus levels) detected major changes in microbial taxonomybetween the diabetic groups and the non- 
diabetic controlgroup (Table 4). At the phylum level, the rat intestinalmicrobiota is dominated by Firmicutes 
and Bacteroidetes(together harbouring on average 94.08% of sequences;Table 4). The relative  
abundances of Bacteroidetes andFirmicutes were higher and lower, respectively in thediabetic-high GABA 
group, compared with the non-diabeticcontrol group (P<0.05) (Table 4). The ratio of 
Bacteroides:Firmicutes was subsequently lowest in the diabetic-highGABA group, compared with the non- 
diabetic controlgroup (Table 4). Relative abundances of Actinobacteriawere higher in the diabetic-control 
and diabetic L. brevisDPC 6108 groups, compared with the non-diabetic controlgroup (P<0.01) (Table 4). 
Cyanobacteria were higher in thediabetic-low GABA group, compared with the diabeticcontrol and diabetic 
L. brevis DPC 6108 groups (P<0.05)(Table 4). Proteobacteria were higher in the diabeticlowGABA 
(P<0.05) and the diabetic L. brevis DPC 6108(P<0.01) groups, compared with the non-diabetic 
controlgroup (Table 4). A comprehensive list of the most abundant proportions that significantly differed 
between the groups at family and genus levels are outlined in Table 4. 
 
 4. Discussion 
In the present study, L. brevis DPC 6108 supplementationfor 5 weeks significantly increased (69%) serum 
insulinlevels in healthy rats. From this, we subsequently conducteda second experiment to investigate 
whether dietary GABAand /or L. brevis DPC 6108 could prevent STZ-inducedT1 D.Oral administration of 
GABA and L. brevis DPC 6108 for9 weeks had no effect on the prevention of STZ-inducedT1 D as rats 
developed an overt basal hypoinsulinemia andextreme hyperglycemia, suggesting a drastic decrease inβ-
cell numbers. Our data support the results of a previousstudy which reported a significant decrease in cell 
massof the pancreas isolated from STZ-induced rats withconcomitant insulin depletion, not restored by 
GABA treatment (Adeghate and Ponery, 2002). However, theycontradict studies showing that oral GABA 
administrationattenuated hyperglycemia and oxidative stress in STZinduceddiabetic rats (Nakagawa et al., 
2005), whereasGABA intraperitoneal injections prevented and reversed high glucose levels caused by 
multiple low doses of STZ inmice (Soltani et al., 2011). GABA therapy was also reportedto be beneficial in 
other models of diabetes, such as thenon-obese diabetic (NOD) mouse model of T1 D (Tian etal., 2011 a) 
and high-fat diet (HFD)-fed mouse model ofT2D (Tian et al., 2011 b). In these studies, the positive effectof 
GABA was related to the modulation of the immuneresponse present in diabetes. 
The results obtained in this study support the hypothesisthat the beneficial effect of GABA may be 
primarily dueto modulation of immune cell function. In animal models,such as the NOD mouse, HFD-
induced T2D mouse and themultiple low-dose STZ-induced diabetes mouse, pancreaticislets are partially 
damaged and the inflammatory processcauses the further loss of β-cells. In contrast, the 
procedurecommonly applied in rats and used in this study inducesT1 D with one single dose of STZ, 
destroying the β-cellsrapidly and completely, with absence of an immune response(Wu and Huan, 2008). 
In this case, GABA supplementationmay have no effect, as there is no immune response tobe attenuated. 
However, beside its anti-inflammatoryeffect, evidence suggests that GABA may stimulate β-cellreplication 
and inhibit apoptosis in vitro (Soltani et al.,2011) and in vivo (Tian et al., 2013), if a sufficient residualislet 
mass is present to permit recovery. The high levels ofglucose and low levels of insulin in diabetic rats 
indicatedan extensive loss of β-cell mass that could not be reversedby dietary GABA in this study. 
Probiotic administration in STZ-induced diabeticanimals previously displayed contrasting results 
onglucose homeostasis. Davari et al. (2013) and Lin et al. (2014) reported a significant decrease in 
glucose levels inanimals receiving a probiotic mix containing Lactobacillusacidophilus, Bifidobacterium 
lactis and Lactobacillusfermentum and Lactobacillus reuteri, respectively,compared with diabetic controls, 
as was seen in this study.Tabuchi et al. (2003) and Yadav et al. (2008) observed animprovement in 
glucose tolerance following Lactobacillusrhamnosus GG, L. acidophilus and Lactobacillus 
caseisupplementation, whereas Zarfeshani et al. (2011) foundno significant differences in blood glucose 
levels followingL. casei supplementation. Increased serum insulin levels inprobiotic-fed groups were 
demonstrated only in the studiesby Davari et al. (2013) and Tabuchi et al. (2003). Althoughwe observed a 
significant increase in serum insulin levelsin healthy rats receiving L. brevis DPC 6108 (Experiment 
1:69%), the same was not seen in diabetic rats in Experiment2, most likely because the β-cell mass was 
considerablydestroyed. However, although supplementation of L. brevisDPC 6108 did not affect serum 
glucose levels in healthyrats, it significantly reduced glucose levels in diabeticrats, compared with diabetic 
controls (23%). The balancebetween glucose uptake, regulated mainly by the CNS andglucose production 
from the liver is complex and involvesseveral mechanisms. Leptin has been shown to inducereduction of 
food intake in diabetic animals, loweringplasma glucose levels (Sindelar et al., 1999), and actingin the 
CNS inhibiting hepatic glucose production andincreasing glucose utilisation by other tissues (German 
etal., 2011). Food intake and leptin levels were not alteredin the diabetic group receiving the bacteria, 
compared tothe other diabetic groups in the present study. Moreover,other metabolic markers involved in 
glucose homeostasis(insulin, glucagon, GLP-1 and GIP) were similar amongall diabetic groups and did 
not account for this reductionin glucose levels in the L. brevis DPC 6108 supplementedgroup. 
Explanations for the difference in glucose levelmay be related to increased glucose excretion in the 
urine,reduced hepatic glucose production or increased glucoseuptake by tissues. 
GABA released by β-cells plays a role in regulating glucagonsecretion from α-cells (Bailey et al., 2007; 
Bansal et al.,201 1). In this study, the extensive damage to the β-cellmass caused by STZ most likely 
reduced the amountof endogenous GABA (Adeghate and Ponery, 2002),stimulating glucagon release in 
all diabetic groups. Despitehigher circulating levels of GABA detected in the diabetichighGABA 
supplemented group, this did not suppressglucagon. The increased glucagon secretion together withthe 
low level of circulating insulin in all diabetic rats, mostlikely caused insufficient suppression of hormone-
sensitivelipase activity in the adipose tissue, causing hyperglycaemiaand hypertriglyceridemia. Increased 
food intake alsocontributed to hypertriglyceridemia. Moreover, highlevels of glucose may have stimulated 
hepatic triglycerideproduction leading to the fatty liver observed in diabetic rats(Dallman and Bhatnagar, 
2011; Tamura and Shimomura,2005). 
The marked hyperphagia in diabetic animals has beenassociated with insulin and leptin deficiencies 
(Dallman andBhatnagar, 2011; Sindelar et al., 1999; Sipols et al., 1995).Hyperphagia might have caused 
small intestine hypertrophy(Saudek and Young, 1981) in all diabetic rats. With increasedintestinal mass, 
the density of gastrointestinal cells alsoincreases, altering gut motility and secretion/absorption(El-Salhy, 
2001). Increased faecal output, diarrhoea andsignificantly higher PYY levels were found in the serumof all 
diabetic rats. PYY secretion has also been shown todelay intestinal transit and gastric emptying, thus 
reducingdiarrhoea (El-Salhy, 2001). Small intestinal hypertrophyis also associated with increased 
intestinal cholesterolsynthesis and absorption in diabetes (Feingold, 1 989;Gleeson et al., 2000). 
Interestingly, total serum cholesterol was increased only in diabetic rats receiving the high doseGABA, 
compared with the non-diabetic controls. As foodintake and intestinal length were similar among all 
diabeticgroups as well as hepatic cholesterol levels, the mechanismby which the high dose of GABA 
mediated the changes inserum cholesterol observed in the current study remainsto be elucidated. 
Intestinal microbiota composition, diversity and metaboliteproduction were previously shown to be greatly 
affected bySTZ-induced T1 D (Patterson et al., 2015). Supplementationwith low dose GABA attenuated the 
significant reductionto microbial diversity induced by T1 D, apparent in allother diabetic groups. Distinct 
phylogenetic alterationsin microbial composition were apparent between alldiabetic groups, compared with 
non-diabetic controls.Most notably and similar to the previous study by Pattersonet al. (2015), the ratio of 
Bacteroidetes: Firmicutes wasreduced following T1 D induction. This ratio was furtherreduced following all 
treatments. Interestingly, thetreatment with high-GABA had the most pronouncedeffect on the relative 
proportions of Bacteroidetes andFirmicutes. Of course, the literature has implicated thisratio to be of 
significance in numerous disease states(Frank et al., 2011; Graessler et al., 2013). However, ourresults 
are in contrast to previous studies which havedescribed a decrease in the Firmicutes: Bacteroidetes 
ratioassociated with T1 D (Giongo et al., 2011; Murri et al.,201 3). Actinobacteria, previously reported as 
significantlyincreased following STZ-induced T1 D (Patterson et al.,201 5), was only significantly 
increased in the caecal contentsof the diabetic control and diabetic L. brevis DPC 61 08rats, compared with 
the non- diabetic control rats. Theincreased Actinobacteria linked with diabetes previouslycorrelated with 
the reduced microbial diversity of theserats (Patterson et al., 2015) and so it appears that 
GABAsupplementation normalised Actinobacteria levels to thoseseen in the non-diabetic control group. In 
accordancewith this increase in Actinobacteria, Bifidobacteriaceaeand Bifidobacterium were also 
increased in the diabeticcontrol,diabetic-low GABA and diabetic-L. brevis DPC61 08 groups, compared 
with the non-diabetic controlgroup. Furthermore, taxa at lower relative proportionsdrove the significant 
differences between the groups, but noclear pattern existed between the non-diabetic control anddiabetic-
control groups, compared to any of the treatmentgroups. This emphasises that STZ-induced T1 D 
severelyaltered microbial compositions of the rats, by a random anduncontrolled method. While 
compositional changes in therelative abundances of intestinal microbiota were presentbetween diabetic 
groups and the non-diabetic controls,the treatments did not appear to have any significant effecton 
taxonomy and so we cannot conclude that GABA orL. brevis DPC 61 08 supplementation had any 
significanthealth-promoting effect on the intestinal microbiota. 
In conclusion, our results indicate that the use of GABAand GABA-producing probiotic L. brevis DPC 61 08 
isnot effective in the prevention of diabetic symptoms, as aminimum number of healthy β-cells may be 
necessary forthe efficacy of treatments against T1 D. 
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